O	O	O	0	10	Inhibition	Inhibition	B-NP	NN	O	7	SUB	O
O	O	O	11	13	of	of	B-PP	IN	O	1	NMOD	O
T11	B-Entity	B-Entity	14	21	nuclear	nuclear	B-NP	JJ	B-protein	5	NMOD	B-protein
T11	I-Entity	I-Entity	22	28	factor	factor	I-NP	NN	I-protein	5	NMOD	I-protein
T11	I-Entity	I-Entity	29	35	kappaB	kappaB	I-NP	NN	I-protein	6	NMOD	I-protein
O	O	O	36	46	activation	activation	I-NP	NN	O	2	PMOD	O
O	O	O	47	57	attenuates	attenuate	B-VP	VBZ	O	0	ROOT	O
O	O	O	58	67	apoptosis	apoptosis	B-NP	NN	O	9	NMOD	O
O	O	O	68	78	resistance	resistance	I-NP	NN	O	7	OBJ	O
O	O	O	79	81	in	in	B-PP	IN	O	9	NMOD	O
O	O	O	82	90	lymphoid	lymphoid	B-NP	JJ	B-cell_type	12	NMOD	B-cell_type
O	O	O	91	96	cells	cell	I-NP	NNS	I-cell_type	10	PMOD	I-cell_type
O	O	O	96	97	.	.	O	.	O	7	P	O

O	O	O	99	104	Death	Death	B-NP	NN	B-protein	4	NMOD	B-protein
O	O	O	104	105	-	-	O	HYPH	I-protein	1	P	I-protein
O	O	O	105	113	inducing	induce	B-VP	VBG	I-protein	4	NMOD	I-protein
O	O	O	114	121	ligands	ligand	B-NP	NNS	I-protein	22	SUB	I-protein
O	O	O	122	123	(	(	O	(	O	7	DEP	O
O	O	O	123	127	DILs	DIL	B-NP	NNS	B-protein	7	DEP	B-protein
O	O	O	127	128	)	)	O	)	O	4	NMOD	O
O	O	O	129	133	such	such	B-PP	JJ	O	9	PMOD	O
O	O	O	134	136	as	as	I-PP	IN	O	4	NMOD	O
T1	B-Protein	B-Protein	137	142	tumor	tumor	B-NP	NN	B-protein	13	NMOD	B-protein
T1	I-Protein	I-Protein	143	151	necrosis	necrosis	I-NP	NN	I-protein	13	NMOD	I-protein
T1	I-Protein	I-Protein	152	158	factor	factor	I-NP	NN	I-protein	13	NMOD	I-protein
T1	I-Protein	I-Protein	159	164	alpha	alpha	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	O	165	166	(	(	O	(	O	16	DEP	O
T2	B-Protein	B-Protein	166	174	TNFalpha	TNFalpha	B-NP	NN	B-protein	16	DEP	B-protein
O	O	O	174	175	)	)	O	)	O	13	NMOD	O
O	O	O	176	178	or	or	O	CC	O	20	NMOD	O
O	O	O	179	182	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	183	192	cytotoxic	cytotoxic	I-NP	JJ	O	20	NMOD	O
O	O	O	193	197	drug	drug	I-NP	NN	O	21	NMOD	O
O	O	O	198	209	doxorubicin	doxorubicin	I-NP	NN	O	9	PMOD	O
O	O	O	210	214	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	215	219	been	be	I-VP	VBN	O	22	VC	O
O	O	O	220	225	shown	show	I-VP	VBN	O	23	VC	O
O	O	O	226	228	to	to	I-VP	TO	O	26	VMOD	O
O	O	O	229	237	activate	activate	I-VP	VB	O	24	VMOD	O
O	O	O	238	239	a	a	B-NP	DT	O	30	NMOD	O
T12	B-Entity	B-Entity	240	247	nuclear	nuclear	I-NP	JJ	B-protein	30	NMOD	B-protein
T12	I-Entity	I-Entity	248	254	factor	factor	I-NP	NN	I-protein	30	NMOD	I-protein
T12	I-Entity	I-Entity	255	261	kappaB	kappaB	I-NP	NN	I-protein	36	NMOD	I-protein
O	O	O	262	263	(	(	O	(	O	33	DEP	O
T13	B-Entity	B-Entity	263	271	NFkappaB	NFkappaB	B-NP	NN	B-protein	33	DEP	B-protein
O	O	O	271	272	)	)	O	)	O	30	NMOD	O
O	O	O	272	273	-	-	B-NP	HYPH	O	36	NMOD	O
O	O	O	273	282	dependent	dependent	I-NP	JJ	O	36	NMOD	O
O	O	O	283	290	program	program	I-NP	NN	O	26	OBJ	O
O	O	O	291	295	that	that	B-NP	WDT	O	36	NMOD	O
O	O	O	296	299	may	may	B-VP	MD	O	37	SBAR	O
O	O	O	300	306	rescue	rescue	I-VP	VB	O	38	VC	O
O	O	O	307	312	cells	cell	B-NP	NNS	O	39	OBJ	O
O	O	O	313	317	from	from	B-PP	IN	O	39	VMOD	O
O	O	O	318	327	apoptosis	apoptosis	B-NP	NN	O	43	NMOD	O
O	O	O	328	337	induction	induction	I-NP	NN	O	41	PMOD	O
O	O	O	337	338	.	.	O	.	O	22	P	O

O	O	O	339	341	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	342	353	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	O	354	358	here	here	B-ADVP	RB	O	2	VMOD	O
O	O	O	359	363	that	that	B-SBAR	IN	O	2	VMOD	O
T3	B-Protein	B-Protein	364	369	TRAIL	TRAIL	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	370	371	(	(	O	(	O	14	DEP	O
T4	B-Protein	B-Protein	371	374	TNF	TNF	B-NP	NN	B-protein	10	NMOD	B-protein
T4	I-Protein	I-Protein	374	375	-	-	O	HYPH	O	7	P	O
T4	I-Protein	I-Protein	375	382	related	relate	B-NP	VBN	O	10	NMOD	O
T4	I-Protein	I-Protein	383	392	apoptosis	apoptosis	I-NP	NN	O	14	DEP	O
T4	I-Protein	I-Protein	392	393	-	-	O	HYPH	O	10	P	O
T4	I-Protein	I-Protein	393	401	inducing	induce	B-VP	VBG	O	10	NMOD	O
T4	I-Protein	I-Protein	402	408	ligand	ligand	B-NP	NN	O	12	OBJ	O
O	O	O	408	409	)	)	O	)	O	5	NMOD	O
O	O	O	409	410	,	,	O	,	O	19	P	O
O	O	O	411	412	a	a	B-NP	DT	O	19	NMOD	O
O	O	O	413	421	recently	recently	I-NP	RB	O	18	AMOD	O
O	O	O	422	432	identified	identify	I-NP	VBN	O	19	NMOD	O
O	O	O	433	436	DIL	DIL	I-NP	NN	B-protein	22	SUB	B-protein
O	O	O	436	437	,	,	O	,	O	19	P	O
O	O	O	438	442	also	also	B-ADVP	RB	O	22	VMOD	O
O	O	O	443	452	activates	activate	B-VP	VBZ	O	4	SBAR	O
T14	B-Entity	B-Entity	453	461	NFkappaB	NFkappaB	B-NP	NN	B-protein	22	OBJ	B-protein
O	O	O	462	464	in	in	B-PP	IN	O	23	NMOD	O
O	O	O	465	473	lymphoid	lymphoid	B-NP	JJ	B-cell_line	27	NMOD	B-cell_line
O	O	O	474	478	cell	cell	I-NP	NN	I-cell_line	27	NMOD	I-cell_line
O	O	O	479	484	lines	line	I-NP	NNS	I-cell_line	24	PMOD	I-cell_line
O	O	O	485	487	in	in	B-PP	IN	O	22	VMOD	O
O	O	O	488	489	a	a	B-NP	DT	O	30	NMOD	O
O	O	O	490	497	kinetic	kinetic	I-NP	JJ	O	28	PMOD	O
O	O	O	498	505	similar	similar	I-NP	JJ	O	30	NMOD	O
O	O	O	506	508	to	to	B-PP	TO	O	31	AMOD	O
T5	B-Protein	B-Protein	509	517	TNFalpha	TNFalpha	B-NP	NN	B-protein	32	PMOD	B-protein
O	O	O	517	518	.	.	O	.	O	2	P	O

T15	B-Entity	B-Entity	519	527	NFkappaB	NFkappaB	B-NP	NN	B-protein	2	NMOD	B-protein
O	O	O	528	536	activity	activity	I-NP	NN	O	3	SUB	O
O	O	O	537	539	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	540	551	independent	independent	B-ADJP	JJ	O	3	PRD	O
O	O	O	552	556	from	from	B-PP	IN	O	4	AMOD	O
T6	B-Protein	B-Protein	557	561	FADD	FADD	B-NP	NN	B-protein	12	NMOD	B-protein
O	O	O	561	562	,	,	O	,	O	12	P	O
O	O	O	563	571	caspases	caspas	B-NP	NNS	B-protein	12	NMOD	B-protein
O	O	O	571	572	,	,	O	,	O	12	P	O
O	O	O	573	576	and	and	O	CC	O	12	NMOD	O
O	O	O	577	586	apoptosis	apoptosis	B-NP	NN	O	12	NMOD	O
O	O	O	587	596	induction	induction	I-NP	NN	O	5	PMOD	O
O	O	O	596	597	.	.	O	.	O	3	P	O

O	O	O	598	600	To	To	B-VP	TO	O	2	VMOD	O
O	O	O	601	606	study	study	I-VP	VB	O	23	VMOD	O
O	O	O	607	610	the	the	B-NP	DT	O	4	NMOD	O
O	O	O	611	620	influence	influence	I-NP	NN	O	2	OBJ	O
O	O	O	621	623	of	of	B-PP	IN	O	4	NMOD	O
T16	B-Entity	B-Entity	624	632	NFkappaB	NFkappaB	B-NP	NN	B-protein	7	NMOD	B-protein
O	O	O	633	641	activity	activity	I-NP	NN	O	5	PMOD	O
O	O	O	642	644	on	on	B-PP	IN	O	4	NMOD	O
O	O	O	645	654	apoptosis	apoptosis	B-NP	NN	O	8	PMOD	O
O	O	O	655	663	mediated	mediate	B-VP	VBN	O	9	NMOD	O
O	O	O	664	666	by	by	B-PP	IN	O	10	VMOD	O
T7	B-Protein	B-Protein	667	672	TRAIL	TRAIL	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	672	673	,	,	O	,	O	19	P	O
T8	B-Protein	B-Protein	674	678	CD95	CD95	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	678	679	,	,	O	,	O	19	P	O
T9	B-Protein	B-Protein	680	688	TNFalpha	TNFalpha	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	688	689	,	,	O	,	O	19	P	O
O	O	O	690	692	or	or	O	CC	O	19	NMOD	O
O	O	O	693	704	doxorubicin	doxorubicin	B-NP	NN	O	11	PMOD	O
O	O	O	704	705	,	,	O	,	O	23	P	O
T17	B-Entity	B-Entity	706	714	NFkappaB	NFkappaB	B-NP	NN	B-protein	22	NMOD	B-protein
O	O	O	715	725	activation	activation	I-NP	NN	O	23	SUB	O
O	O	O	726	729	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	730	739	inhibited	inhibit	I-VP	VBN	O	23	VC	O
O	O	O	740	745	using	use	B-VP	VBG	O	23	VMOD	O
O	O	O	746	749	the	the	B-NP	DT	O	28	NMOD	O
T18	B-Entity	B-Entity	750	760	proteasome	proteasome	I-NP	NN	B-protein	28	NMOD	B-protein
O	O	O	761	770	inhibitor	inhibitor	I-NP	NN	O	46	NMOD	O
O	O	O	771	772	N	N	I-NP	NN	O	46	NMOD	O
O	O	O	772	773	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	O	773	779	acetyl	acetyl	I-NP	NN	O	46	NMOD	O
O	O	O	779	780	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	O	780	781	L	L	I-NP	NN	O	46	NMOD	O
O	O	O	781	782	-	-	B-NP	HYPH	O	46	P	O
O	O	O	782	790	leucinyl	leucinyl	I-NP	NN	O	46	NMOD	O
O	O	O	790	791	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	O	791	792	L	L	I-NP	NN	O	46	NMOD	O
O	O	O	792	793	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	O	793	801	leucinyl	leucinyl	I-NP	NN	O	46	NMOD	O
O	O	O	801	802	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	O	802	803	L	L	I-NP	NN	O	46	NMOD	O
O	O	O	803	804	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	O	804	815	norleucinal	norleucinal	I-NP	JJ	O	46	NMOD	O
O	O	O	816	818	or	or	I-NP	CC	O	46	NMOD	O
O	O	O	819	828	transient	transient	I-NP	JJ	O	46	NMOD	O
O	O	O	829	843	overexpression	overexpression	I-NP	NN	O	25	OBJ	O
O	O	O	844	846	of	of	B-PP	IN	O	46	NMOD	O
O	O	O	847	853	mutant	mutant	B-NP	JJ	B-protein	49	NMOD	B-protein
T10	B-Protein	B-Protein	854	866	IkappaBalpha	IkappaBalpha	I-NP	NN	I-protein	47	PMOD	I-protein
O	O	O	866	867	.	.	O	.	O	23	P	O

O	O	O	868	879	Sensitivity	Sensitivity	B-NP	NN	O	6	SUB	O
O	O	O	880	883	for	for	B-PP	IN	O	1	NMOD	O
O	O	O	884	893	induction	induction	B-NP	NN	O	2	PMOD	O
O	O	O	894	896	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	897	906	apoptosis	apoptosis	B-NP	NN	O	4	PMOD	O
O	O	O	907	910	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	911	919	markedly	markedly	I-VP	RB	O	6	VMOD	O
O	O	O	920	929	increased	increase	I-VP	VBN	O	6	VC	O
O	O	O	930	932	by	by	B-PP	IN	O	8	VMOD	O
O	O	O	933	938	these	these	B-NP	DT	O	11	NMOD	O
O	O	O	939	949	treatments	treatment	I-NP	NNS	O	9	PMOD	O
O	O	O	950	952	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	953	962	apoptosis	apoptosis	B-NP	NN	O	16	NMOD	O
O	O	O	963	972	sensitive	sensitive	I-NP	JJ	O	13	AMOD	O
O	O	O	973	977	cell	cell	I-NP	NN	O	16	NMOD	O
O	O	O	978	983	lines	line	I-NP	NNS	O	12	PMOD	O
O	O	O	983	984	.	.	O	.	O	6	P	O

O	O	O	985	993	Moreover	Moreover	B-ADVP	RB	O	29	VMOD	O
O	O	O	993	994	,	,	O	,	O	29	P	O
O	O	O	995	999	both	both	B-PP	CC	O	29	VMOD	O
O	O	O	1000	1002	in	in	I-PP	IN	O	3	PMOD	O
O	O	O	1003	1007	cell	cell	B-NP	NN	B-cell_line	6	NMOD	B-cell_line
O	O	O	1008	1013	lines	line	I-NP	NNS	I-cell_line	4	PMOD	I-cell_line
O	O	O	1014	1017	and	and	B-PP	CC	O	3	PMOD	O
O	O	O	1018	1020	in	in	B-PP	IN	O	3	PMOD	O
O	O	O	1021	1028	primary	primary	B-NP	JJ	B-cell_type	11	NMOD	B-cell_type
O	O	O	1029	1037	leukemia	leukemia	I-NP	NN	I-cell_type	11	NMOD	I-cell_type
O	O	O	1038	1043	cells	cell	I-NP	NNS	I-cell_type	8	PMOD	I-cell_type
O	O	O	1044	1048	that	that	B-NP	WDT	O	11	NMOD	O
O	O	O	1049	1052	are	be	B-VP	VBP	O	12	SBAR	O
O	O	O	1053	1062	resistant	resistant	B-ADJP	JJ	O	13	PRD	O
O	O	O	1063	1070	towards	towards	B-PP	IN	O	14	AMOD	O
O	O	O	1071	1080	induction	induction	B-NP	NN	O	15	PMOD	O
O	O	O	1081	1083	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	1084	1093	apoptosis	apoptosis	B-NP	NN	O	17	PMOD	O
O	O	O	1094	1096	by	by	B-PP	IN	O	16	NMOD	O
O	O	O	1097	1101	DILs	DIL	B-NP	NNS	B-protein	22	NMOD	B-protein
O	O	O	1102	1105	and	and	O	CC	O	22	NMOD	O
O	O	O	1106	1117	doxorubicin	doxorubicin	B-NP	NN	O	19	PMOD	O
O	O	O	1117	1118	,	,	O	,	O	29	P	O
O	O	O	1119	1133	antagonization	antagonization	B-NP	NN	O	29	SUB	O
O	O	O	1134	1136	of	of	B-PP	IN	O	24	NMOD	O
T19	B-Entity	B-Entity	1137	1145	NFkappaB	NFkappaB	B-NP	NN	B-protein	27	NMOD	B-protein
O	O	O	1146	1154	activity	activity	I-NP	NN	O	25	PMOD	O
O	O	O	1155	1164	partially	partially	B-ADVP	RB	O	29	VMOD	O
O	O	O	1165	1173	restored	restore	B-VP	VBD	O	0	ROOT	O
O	O	O	1174	1183	apoptosis	apoptosis	B-NP	NN	O	31	NMOD	O
O	O	O	1184	1195	sensitivity	sensitivity	I-NP	NN	O	29	OBJ	O
O	O	O	1195	1196	.	.	O	.	O	29	P	O

O	O	O	1197	1202	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1203	1207	data	datum	I-NP	NNS	O	3	SUB	O
O	O	O	1208	1215	suggest	suggest	B-VP	VBP	O	0	ROOT	O
O	O	O	1216	1220	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1221	1231	inhibition	inhibition	B-NP	NN	O	9	SUB	O
O	O	O	1232	1234	of	of	B-PP	IN	O	5	NMOD	O
T20	B-Entity	B-Entity	1235	1243	NFkappaB	NFkappaB	B-NP	NN	B-protein	8	NMOD	B-protein
O	O	O	1244	1254	activation	activation	I-NP	NN	O	6	PMOD	O
O	O	O	1255	1258	may	may	B-VP	MD	O	4	SBAR	O
O	O	O	1259	1266	provide	provide	I-VP	VB	O	9	VC	O
O	O	O	1267	1268	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	1269	1278	molecular	molecular	I-NP	JJ	O	13	NMOD	O
O	O	O	1279	1287	approach	approach	I-NP	NN	O	10	OBJ	O
O	O	O	1288	1290	to	to	B-VP	TO	O	15	VMOD	O
O	O	O	1291	1299	increase	increase	I-VP	VB	O	13	NMOD	O
O	O	O	1300	1309	apoptosis	apoptosis	B-NP	NN	O	17	NMOD	O
O	O	O	1310	1321	sensitivity	sensitivity	I-NP	NN	O	15	OBJ	O
O	O	O	1322	1324	in	in	B-PP	IN	O	15	VMOD	O
O	O	O	1325	1335	anticancer	anticancer	B-NP	JJ	O	20	NMOD	O
O	O	O	1336	1345	treatment	treatment	I-NP	NN	O	18	PMOD	O
O	O	O	1345	1346	.	.	O	.	O	3	P	O
